Today, Andon Health Co.Ltd(002432) announced that the following orders for ihealth covid-19 antigen home self-test OTC kit from New York and Massachusetts received by the company’s U.S. subsidiary took effect on the day of receipt of the order, with a total order amount of US $65.31 million (including freight), about RMB 416 million.
In addition, the ihealth kit sales contract signed with the Department of health of New York State took effect on January 10 local time. The total amount of contract price tax is 120 million US dollars (including freight), about 764 million yuan.
Coincidentally, just before Andon Health Co.Ltd(002432) released the major business contracts signed by the U.S. subsidiary, the Shenzhen Stock Exchange just sent a letter of concern to the company, asking Andon Health Co.Ltd(002432) to explain whether the disclosure is cautious and objective, and whether there are exaggerated publicity and misleading tips to cater to the hot market concepts and hype the stock price.
It is mentioned that it is required to explain the reason why the announcement of the company only discloses the test results of four samples with CT value less than or equal to 21.59, but does not disclose the test results of seven samples with CT value greater than 21.59, and whether there is a situation in which the positive detection rate of all samples is confused with the positive detection rate of some samples to mislead investors, Whether the disclosure of the test results of the experimental report in the above announcement is complete, whether there is a situation of selectively disclosing some information to hype the stock price , and explain the reasons.
The announcement mentioned in the attention letter of Shenzhen stock exchange is the announcement on the subsidiary’s receipt of the performance test report of ihealth covid-19 antigen home self-test OTC kit against omiron variant virus issued on Andon Health Co.Ltd(002432) January 7.
The announcement shows that 100% of the ohealth covid-19 antigen home self-test OTC Kit (hereinafter referred to as “ihealth kit”) detected Omicron active virus samples with a maximum CT value of 21.59 (n = 5). On the same day, the company’s share price rose 6.05%.
At the close today, Andon Health Co.Ltd(002432) shares rose again to close at 62.22 yuan / share, with a total market value of 29.8 billion yuan. Since November 2021, the company’s share price has increased tenfold.
After the surge, Andon Health Co.Ltd(002432) has become the focus of regulators. Today’s concern letter is the fourth concern letter received by the company since November last year.
Today, Andon Health Co.Ltd(002432) also issued a change announcement, saying that the company previously submitted the proposal on using family self-test box to realize Omicron covid-19 epidemic prevention 1 + 1 to Tianjin epidemic prevention and control headquarters. At present, relevant departments are studying the proposal, and it is uncertain whether the proposal will be adopted.
